3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Neoplasms
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
pembrolizumab
126
Cisplatin
48
Cetuximab
46
Nivolumab
36
Carboplatin
33
Paclitaxel
28
Fluorouracil
26
Docetaxel
17
Cyclophosphamide
12
avelumab
11
Radiotherapy
11
cemiplimab
10
atezolizumab
10
durvalumab
9
Ipilimumab
8
spartalizumab
7
fludarabine
7
budigalimab
7
Gemcitabine
7
Capecitabine
7
tremelimumab
6
lenvatinib
6
Pemetrexed
6
130-nm albumin-bound paclitaxel
6
epacadostat
5
Fulvestrant
5
zimberelimab
4
tislelizumab
4
Trastuzumab
4
Oxaliplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Squamous Cell Carcinoma of Head and Neck
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts